News | January 13, 2025
Apotex acquires US rights to PROVIGIL and NUVIGIL
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Acquisition expands high-value medical platform
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
ICMR will continue to track trends in HMPV circulation throughout the year
Subscribe To Our Newsletter & Stay Updated
